Techvest 7th Annual Healthcare Conference Presenter Profiles.NEW YORK New York, state, United States New York, Middle Atlantic state of the United States. It is bordered by Vermont, Massachusetts, Connecticut, and the Atlantic Ocean (E), New Jersey and Pennsylvania (S), Lakes Erie and Ontario and the Canadian province of -- Techvest 7th Annual Healthcare Conference takes place 07 - 09 Nov. at the New York Palace
New York City City (pop., 2000: 8,008,278), southeastern New York, at the mouth of the Hudson River. The largest city in the U.S. . For in-depth information about the event visit http://www.rodmanandrenshaw.com/index.htm. Below are profiles from Techvest 7th Annual Healthcare Conference presenters. News releases, web cast advisories, and photos are available at http://home.businesswire.com/portal/site/bwges-techvest-health-05/. Business Wire is the official news wire service for the Techvest 7th Annual Healthcare Conference. Company: Active Biotech AB Ticker Symbol & Exchange: ACTI.SE SEK Investor Relations Contact: Cecilia Hofvander Investor Relations Contact Phone: +46 46 19 11 22 or +46 701 89 11 22 Web: www.activebiotech.com Date of Presentation: Nov 8 Active Biotech AB is a biotechnology company focusing on research and development of pharmaceuticals. Active Biotech has a strong R&D portfolio with pipeline products focused on autoimmune/inflammatory diseases and cancer. Most advanced projects are laquinimod, an orally administered small molecule with unique immunomodulatory properties for the treatment of multiple sclerosis, as well as ANYARA for use in cancer immunotherapy with the primary indication non-small cell lung cancer Lung Cancer, Non-Small Cell Definition Non-small cell lung cancer (NSCLC) is a disease in which the cells of the lung tissues grow uncontrollably and form tumors. Description There are two kinds of lung cancers, primary and secondary. . Further key projects in clinical development comprise the three orally administered compounds TASQ TASQ Transparent Auto-Switch Quality (Quitum Technologies) TASQ Tactical Airlift Squadron for prostate cancer prostate cancer, cancer originating in the prostate gland. Prostate cancer is the leading malignancy in men in the United States and is second only to lung cancer as a cause of cancer death in men. 57-57 for SLE SLE systemic lupus erythematosus. SLE abbr. systemic lupus erythematosus Systemic lupus erythematosus (SLE) and RhuDex(R) for RA. Company: Adeza Biomedical Ticker Symbol & Exchange: Nasdaq: ADZA Investor Relations Contact: Brandi Floberg Investor Relations Contact Phone: 310-691-7100 Web: www.adeza.com Date of Presentation: November 9, 2005 at 11:15 a.m. ET Adeza designs, manufactures and markets innovative products for women's health Women's Health Definition Women's health is the effect of gender on disease and health that encompasses a broad range of biological and psychosocial issues. . Adeza's initial focus is on reproductive healthcare, using its proprietary technologies to predict preterm preterm /pre·term/ (-term´) before completion of the full term; said of pregnancy or of an infant. pre·term adj. birth and assess infertility. Adeza's principal product is a patented diagnostic test, FullTerm(TM) The Fetal Fibronectin Test, which utilizes a single-use, disposable cassette and is analyzed on Adeza's patented TLiIQ(R) System. This product is approved by the U.S. Food and Drug Administration (FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. ) for broad use in assessing the risk of preterm birth. Adeza also markets and sells the E-tegrity(R) Test, an infertility-related test to assess receptivity of the uterus to embryo implantation in women with unexplained infertility. Company: Adherex Technologies Inc. Ticker Symbol & Exchange: AMEX: ADH; TSX: AHX Investor Relations Contact: Melissa Matson Investor Relations Contact Phone: 919-484-8484 Web: www.adherex.com Date of Presentation: Nov. 8, 2005 Adherex Technologies Inc. is a biopharmaceutical company dedicated to the discovery and development of novel cancer therapeutics. We currently have multiple products in the clinical stage of development, including ADH-1 (Exherin(TM)), eniluracil and sodium thiosulfate sodium thiosulfate, Na2S2O3, colorless crystalline compound that is more familiar as the pentahydrate, Na2S2O3·5H2 (STS (Synchronous Transport Signal) The electrical equivalent of the SONET optical signal. In SDH, the European counterpart of SONET, STS is known as STM (Synchronous Transport Module). ). ADH-1, our lead biotechnology compound, selectively targets N-cadherin, a protein present on certain tumor cells and established blood vessels Blood vessels Tubular channels for blood transport, of which there are three principal types: arteries, capillaries, and veins. Only the larger arteries and veins in the body bear distinct names. that feed solid tumors. Eniluracil, an oral dihydropyrimidine dehydrogenase (DPD DPD Department of Planning and Development DPD Dihydropyrimidine Dehydrogenase DPD Dead Peer Detection (Cisco) DPD Division of Parasitic Diseases (US CDC) DPD Dominant Wave Period DPD Drug Product Database ) inhibitor, was previously under development by GlaxoSmithKline for oncology indications. STS, a drug from our specialty pharmaceuticals pipeline, protects against the disabling hearing loss that can often result from treatment with platinum-based chemotherapy drugs. Company: Aksys, Ltd. Ticker Symbol & Exchange: AKSY - NASDAQ Investor Relations Contact: Larry Birch Investor Relations Contact Phone: 847-229-2222 Web: www.aksys.com Date of Presentation: November 9, 2005 - 3:30 p.m. ET Aksys was founded to develop dialysis products and services for patients suffering from kidney failure kidney failure or renal failure Partial or complete loss of kidney function. Acute failure causes reduced urine output and blood chemical imbalance, including uremia. Most patients recover within six weeks. . Our lead product, the Aksys PHD(R) System, is designed to facilitate more frequent dialysis treatments. Studies have shown that increased dialysis frequency can improve the clinical outcomes of patients, as well as reduce morbidity and the associated high cost of patient care. Aksys' approach reflects the following: more frequent treatment is better than less frequent treatment; alternate sites, such as the patient's home, are preferable locations to perform chronic therapy; and an automated, user-friendly dialysis system will make home hemodialysis the preferred alternative therapy for many patients. Improved clinical outcomes in alternate settings also enable the patient to achieve increased quality of life and rehabilitation, the original goal of government-funded ESRD ESRD end-stage renal disease. ESRD End-stage renal disease; chronic or permanent kidney failure. Mentioned in: Dialysis, Kidney ESRD End-stage renal disease, see there programs. Company: Antares Pharma, Inc. Ticker Symbol & Exchange: AIS Investor Relations Contact: Steve Chizzik Investor Relations Contact Phone: 973.912.0980 Web: www.antarespharma.com Date of Presentation: 11/7/05 Antares Pharma is a specialized product development company with patented drug delivery systems combined with injectable device engineering capabilities. The Company's current technology platforms include its ATD ATD Anthropomorphic Test Dummy ATD Attention to Detail ATD Advanced Technology Demonstration AtD Achieving the Dream ATD Atmospheric Technology Division (US National Center for Atmospheric Research) ATD Assistant Technical Director (TM) (Advanced Transdermal Delivery) system, Easy Tec(TM) oral fast-melt technology, and subcutaneous injection technology platforms (Vibex(TM) disposable mini-needle injection device and Valeo(TM) and Vision(R) reusable needle-free injection devices). Antares is committed to leveraging its multiple drug delivery platforms to add value to existing drugs and to create new products and devices. The Company believes that its product pipeline addresses unmet medical needs by reducing side effect profiles, improving safety, increasing effectiveness, and improving patient compliance and convenience. The Company has active partnering programs with several pharmaceutical and distribution companies Company: A.P. Pharma Ticker Symbol & Exchange: Nasdaq: APPA Investor Relations Contact: Zachary Bryant, Assistant VP Investor Relations Contact Phone: (310) 691-7100 Web: www.appharma.com Date of Presentation: Tuesday, November 8, 2005; 4:35 PM A.P. Pharma is a specialty pharmaceutical company focused on the development of ethical (prescription) pharmaceuticals utilizing its proprietary polymer-based drug delivery systems. The Company's primary focus is the development and commercialization of its bioerodible injectable and implantable systems under the trade name Biochronomer(TM). Initial target areas of application for the Company's drug delivery technology include anti-nausea, pain management, inflammation and ophthalmic applications. The Company's product development programs are funded by the sale of common stock in June 2004, royalties from topical products currently marketed by pharmaceutical partners, proceeds from the divestitures of its cosmeceutical cos·me·ceu·ti·cal n. A cosmetic that has or is purported to have medicinal properties. and analytical standards product lines and by fees it receives from collaborative partners. For further information visit the Company's Web site at www.appharma.com. Company: Arena Pharmaceuticals Ticker Symbol & Exchange: NASDAQ: ARNA Investor Relations Contact: Susan Neath Investor Relations Contact Phone: 858-527-3486 Web: www.arenapharm.com Date of Presentation: November 8, 2005 at 10:30 a.m. Arena is a biopharmaceutical company focusing on the development of orally available small molecule drugs for metabolic, cardiovascular, inflammatory and CNS See Continuous net settlement. CNS See continuous net settlement (CNS). diseases. Arena is developing compounds that act on G protein-coupled receptors. Arena's APD APD atrial premature depolarization (see atrial premature complex, under complex ); pamidronate. 356 to treat obesity is in Phase 2b clinical trials, and APD125 to treat insomnia is scheduled to begin Phase 2 clinical trials by year-end. Additionally, Arena and Merck have a partner ship to treat atherosclerosis with an Arena-discovered product candidate currently in a Phase 1 clinical trial phase 1 clinical trial Phase 1 study. See Phase study. . Arena also has a collaboration with Ortho-McNeil, a Johnson & Johnson company, for type 2 diabetes type 2 diabetes n. See diabetes mellitus. . Company: ArQule, Inc. Ticker Symbol & Exchange: NASDAQ: ARQL Investor Relations Contact: William B. Boni Investor Relations Contact Phone: 781-994-0614 Web: http://www.arqule.com Date of Presentation: November 7, 2005 ArQule, Inc., headquartered in Woburn, Mass., is a biotechnology company engaged in the research, development and commercialization of broadly effective cancer drugs with reduced toxicities compared to conventional chemotherapeutics. ArQule's cancer therapies are based on an innovative and proprietary scientific platform called Activated Checkpoint Therapy(SM) that applies a unique molecular biology molecular biology, scientific study of the molecular basis of life processes, including cellular respiration, excretion, and reproduction. The term molecular biology was coined in 1938 by Warren Weaver, then director of the natural sciences program at the Rockefeller approach supported by automated chemistries and intelligent drug design. The Company's lead drug candidate, ARQ (Automatic Repeat reQuest) A method of handling communications errors in which the receiving station requests retransmission if an error occurs. ARQ - Automatic Repeat Request 501, is partnered with Roche and in multiple Phase 1 clinical trials as monotherapy and in combination therapy with chemotherapeutic agents. A number of additional oncology research programs are in preclinical discovery and development. Company: AVANT Immunotherapeutics, Inc. Ticker Symbol & Exchange: Nasdaq: AVAN Investor Relations Contact: Avery (Chip) W. Catlin Investor Relations Contact Phone: 781-433-3148 Web: www.avantimmune.com Date of Presentation: November 7, 2005 at 10:30 AM ET AVANT Immunotherapeutics, Inc. discovers, develops and sells innovative vaccines and therapeutics that harness the human immune system immune system Cells, cell products, organs, and structures of the body involved in the detection and destruction of foreign invaders, such as bacteria, viruses, and cancer cells. Immunity is based on the system's ability to launch a defense against such invaders. to prevent and treat disease. AVANT has developed a broad, well-staged pipeline of products for large, high-value, under-served markets. These include our partner GlaxoSmithKline's oral rotavirus rotavirus /ro·ta·vi·rus/ (ro´tah-vi?rus) any member of the genus Rotavirus. ro´taviral Rotavirus /Ro·ta·vi·rus/ (ro´tah-vi?rus vaccine, Rotarix(R), which GSK GSK GlaxoSmithKline plc (pharmaceutical company) GSK Glycogen Synthase Kinase GSK Gruppentraining Sozialer Kompetenzen (Germany) GSK Greenland Shark (FAO fish species code) is launching worldwide, a treatment to reduce complement-mediated damage associated with cardiac bypass surgery Bypass surgery A surgical procedure that grafts blood vessels onto arteries to reroute the blood flow around blockages in the arteries (arteriosclerosis). and a novel vaccine for cholesterol management. AVANT has assembled technologies that enable the creation of rapid-protecting, single-dose, oral vaccines that remain stable without refrigeration refrigeration, process for drawing heat from substances to lower their temperature, often for purposes of preservation. Refrigeration in its modern, portable form also depends on insulating materials that are thin yet effective. for application in four areas: biodefense, travelers' vaccines, global health, and human food safety. Company: BioBalance Corporation, The Ticker Symbol & Exchange: OTCBB: BBAL Investor Relations Contact: Stan Wunderlich Investor Relations Contact Phone: (800) 625-2236 Web: www.biobalancecorp.com Date of Presentation: Nov 9, 2005 The BioBalance Corporation is a specialty pharmaceutical company focused on innovative treatments for gastrointestinal disorders that are poorly addressed by current therapies. Our lead product, PROBACTRIX(R), is a patented strain of E.coli M17 that displaces pathogenic bacteria Pathogenic bacteria Bacteria that produce illness. Mentioned in: Gastroenteritis in the GI tract addressing what scientists now believe to be a potential root cause of many GI disorders. BioBalance is pursuing accelerated prescription drug approval for pouchitis, a frequent complication following bowel surgery for which no drugs are currently approved. The Company is restructuring as a pure pharmaceutical business, divesting its home healthcare operations to focus exclusively on BioBalance. Company: BioLife Solutions, Inc. Ticker Symbol & Exchange: NASDAQ: OTCBB: BLFS Investor Relations Contact: Jill Bertotti (Allen & Caron) Investor Relations Contact Phone: (949) 474-4300 Web: www.BioLifeSolutions.com Date of Presentation: Nov. 9, 2005 @ 3:30pm BioLife Solutions, Inc. develops, manufactures, and markets low temperature technologies for use in preserving and prolonging the viability of cellular and genetic material for use in cell therapy, tissue engineering and a host of other markets. The Company's patented HypoThermosol(R) and CryoStor(TM) platform technologies are used to provide preservation solutions which significantly enhance storage and transportation capabilities for sensitive biological products. These facilitating technologies extend cell, tissue and organ viability post-preservation, which could, in turn improve clinical outcomes for new and existing cell and tissue therapy applications. Company: Caprius, Inc. Ticker Symbol & Exchange: CAPS.OB Investor Relations Contact: Beverly Tkaczenko Investor Relations Contact Phone: (201) 592-8838 Web: www.caprius.com Date of Presentation: Tuesday, November 8, 2005 - 3:30 PM Caprius, Inc. is a manufacturer of proprietary equipment for the on-site disinfection disinfection, n the process of destroying pathogenic organisms or rendering them inert. disinfection, full oral cavity, n a procedure used to reduce active periodontal disease, usually completed within a certain short time frame. and disposal of infectious medical waste through its subsidiary, M.C.M. Environmental Technologies, Inc. (MCM (MultiChip Module or MicroChip Module) A chip package that contains several bare chips mounted close together on a substrate (base) of some kind. ). The company's innovative SteriMed technology simultaneously shreds and disinfects solid and liquid regulated medical ("red bag") waste, reducing the volume by up to 90% and rendering it harmless for disposal as ordinary waste. The SteriMed units are economical, compact, efficient and convenient, as well as environmentally friendly. The MCM patented technology offers an alternative to hauling and incinerating medical waste. Industry analysts estimate the medical waste market to be approximately $3 billion in the US. Company: Chelsea Therapeutics Ticker Symbol & Exchange: OTC BB: CHTP Investor Relations Contact: Kathryn McNeil Investor Relations Contact Phone: 718-788-2856 Web: www.chelseatherapeutics.com Date of Presentation: November 7, 2005 Chelsea Therapeutics is a biopharmaceutical development company that acquires and develops innovative products for the treatment of a variety of human diseases. Chelsea is currently developing a pipeline of low toxicity, novel antifolate compounds engineered have potent anti-inflammatory and anti-tumor activity to treat a range of immunological disorders. Early clinical data suggests that Chelsea's lead product candidate, CH-1054, may be a safe and effective treatment alternative to methotrexate methotrexate, drug used in halting the growth of actively proliferating tissues. Introduced in the 1950s, it is used in the treatment of leukemia, psoriasis, and non-Hodgkin's lymphoma. for rheumatoid arthritis ("RA") and may have further applications for psoriasis, certain cancers and other immunological disorders. Company: ChemGenex Pharmaceuticals Ticker Symbol & Exchange: NASDAQ:CXSP ASX:CXS Investor Relations Contact: Hershel Berry Investor Relations Contact Phone: 415 392 3385 Web: www.chemgenex.com Date of Presentation: November 8, 2005 ChemGenex Pharmaceuticals is a genomics-driven pharmaceutical development company dedicated to improving the lives of patients by developing novel therapeutics in the areas of oncology, obesity, diabetes and depression. By focusing on validated targets in diseases with genetic components, we seek to bring targeted therapeutics to market that address chronic diseases with high unmet medical need. Our clinical pipeline of cancer drugs, coupled with our partnered discovery and development programs in diabetes and depression, provide us with a solid foundation to meet these objectives. Company: CombiMatrix Corporation Ticker Symbol & Exchange: CBMX Investor Relations Contact: Bret Undem Investor Relations Contact Phone: 425.493.2293 Web: www.combimatrix.com Date of Presentation: Nov. 9th CombiMatrix Corporation is a biotechnology company headquartered near Seattle, Washington, USA, with a wholly owned subsidiary Wholly Owned Subsidiary A subsidiary whose parent company owns 100% of its common stock. Notes: In other words, the parent company owns the company outright and there are no minority owners. , CombiMatrix Molecular Diagnostics headquartered in Irvine, California. CombiMatrix's patented electrochemical electrochemical /elec·tro·chem·i·cal/ (-kem´i-k'l) pertaining to interaction or interconversion of chemical and electrical energies. e·lec·tro·chem·i·cal adj. manufacturing process utilizes standard semiconductor technology, proprietary software, and chemistry to build arrays of materials -- molecule by molecule. The company's CustomArray(TM) products are DNA microarrays, which have uses in pharmaceutical, diagnostic, biotech, and agrochemical agrochemical Any chemical used in agriculture, including chemical fertilizers, herbicides, and insecticides. Most are mixtures of two or more chemicals; active ingredients provide the desired effects, and inert ingredients stabilize or preserve the active ingredients or aid industries as well as in research and government markets. The company also uses its technology in synergistic internal programs for diagnostics, drug development, and biodefense in addition to partnerships for nanomaterials development. Company: Cord Blood America, Inc. Ticker Symbol & Exchange: CBAI OTC BB Investor Relations Contact: Laura Fitzpatrick Investor Relations Contact Phone: 310-432-4090 Web: www.cordblood-america.com Date of Presentation: November 8th Cord Blood America, Inc. ("the Company") is the parent company of Cord Partners, Inc., which provides private cord blood stem cells cord blood stem cells Umbilical cord blood Hematology A therapeutic 'agent' containing concentrated hematopoietic stem cells for Pts with BM depleted–'wiped out' by disease; they are transfused into HLA-identical siblings and used to reconstitute the BM of storage services to families. The Company has achieved rapid growth in its first 2 years of operation, and expects to continue to experience growth as awareness of the cord blood industry grows. Cord Partners sells its service to expectant parents. Families elect to store stem cells from umbilical cord blood umbilical cord blood Transplantation A source of primitive and stem cells that can be used to reconstitute BM destroyed by aplastic anemia or by RT or chemotherapy for CA, lymphoproliferative malignancies. See Bone marrow transplantation, Stem cell therapy. because these stem cells may be used to treat future illnesses in the donor child or other family members. At present, umbilical cord blood stem cells can be used to treat approximately 75 diseases, including various forms of leukemia and anemia, and other immune system disorders. Company: Curon Medical, Inc. Ticker Symbol & Exchange: CURN Investor Relations Contact: RxCommunications Investor Relations Contact Phone: Melody Carey917-322-2571 Web: www.curonmedical.com Date of Presentation: November 9, 2005 Curon Medical, founded in 1997, develops, manufactures and markets innovative proprietary products that employ radiofrequency (RF) energy for the treatment of gastrointestinal disorders. The Company markets the Stretta stret·ta n. pl. stret·te or stret·tas See stretto. [Italian, feminine of stretto, stretto; see stretto.] (R) System for treatment of gastroesophageal reflux disease gastroesophageal reflux disease (GERD) Disorder characterized by frequent passage of gastric contents from the stomach back into the esophagus. Symptoms of GERD may include heartburn, coughing, frequent clearing of the throat, and difficulty in swallowing. (GERD GERD gastroesophageal reflux disease. GERD abbr. gastroesophageal reflux disease GERD ) and the Secca(R) System for treatment of bowel incontinence. Both systems consist of a radiofrequency energy generator and single-use energy delivery devices. The Stretta(R) System received U.S. Food and Drug Administration clearance in April 2000 for the 14-minute RF Treatment for GERD. The Secca(R) System, which received clearance from the FDA in March 2002, enables the 20-minute RF Treatment for Bowel Incontinence. Webcast of presentation can be accessed at http://www.wsw.com/webcast/rrshq7/curn/ Company: CytRx Corporation Ticker Symbol & Exchange: Nasdaq: CYTR Investor Relations Contact: Jody Cain, Senior Vice Preside Investor Relations Contact Phone: (310) 691-7100 Web: www.cytrx.com Date of Presentation: Tuesday, November 8, 2005; 9:45 AM CytRx Corp. is a biopharmaceutical research and development company engaged in the development of products, primarily in the area of small molecules and ribonucleic acid interference (RNAi), in a variety of therapeutic categories. The Company owns three clinical-stage compounds based on its small molecule "molecular chaperone chaperone /chap·er·one/ (shap´er-on) someone or something that accompanies and oversees another. molecular chaperone " co-induction technology, as well as a targeted library of 500 small molecule drug candidates that may be used to screen for new drug candidates. CytRx initiated a Phase II clinical trial Noun 1. phase II clinical trial - a clinical trial on more persons than in phase I; intended to evaluate the efficacy of a treatment for the condition it is intended to treat; possible side effects are monitored phase II with its lead small molecule product candidate arimoclomol for the treatment of amyotrophic lateral sclerosis amyotrophic lateral sclerosis (ALS) (ā'mīətrōf`ik, sklĭrō`sĭs) or motor neuron disease, (ALS Als (äls), Ger. Alsen, island, 121 sq mi (313 sq km), Sønderjylland co., S Denmark, in the Lille Bælt, separated from the mainland by the narrow Alensund. ). Arimoclomol received Orphan Drug and Fast Track designation from the U.S. FDA. CytRx has also licensed exclusive worldwide commercial rights to a novel DNA-based HIV vaccine technology, which has demonstrated positive interim Phase I clinical trial Noun 1. phase I clinical trial - a clinical trial on a few persons to determine the safety of a new drug or invasive medical device; for drugs, dosage or toxicity limits should be obtained phase I results. Company: Discovery Laboratories, Inc. Ticker Symbol & Exchange: DSCO Investor Relations Contact: Lisa Caperelli Investor Relations Contact Phone: 215-488-9413 Web: www.discoverylabs.com Date of Presentation: 11/7/05 Discovery Labs is a biotechnology company developing its proprietary precision-engineered lung surfactant Surfactant Definition Surfactant is a complex naturally occurring substance made of six lipids (fats) and four proteins that is produced in the lungs. It can also be manufactured synthetically. technology (which mimics the function of human lung surfactant) as Surfactant Replacement Therapies for respiratory diseases. Surfactants are produced naturally in the lungs and are essential for breathing. Discovery believes that through its technology, pulmonary surfactants have the potential, for the first time, to address respiratory diseases where there are few or no approved therapies available. Surfaxin(R), Discovery's lead product, has received an Approvable Letter from the FDA and is under review by the EMEA (Europe, Middle East, Africa) Refers to that region of the world. For example, one might see products packaged differently for the UK, EMEA and Asia Pacific markets. , for the prevention of Respiratory Distress Syndrome respiratory distress syndrome or hyaline membrane disease Common complication in newborns, especially after premature birth. Symptoms include very laboured breathing, bluish skin tinge, and low blood oxygen levels. in premature infants. Company: EntreMed, Inc. Ticker Symbol & Exchange: ENMD Investor Relations Contact: Ginny Dunn Investor Relations Contact Phone: 240-864-2643 Web: www.entremed.com Date of Presentation: Tuesday, November 8, 2005 EntreMed, Inc. is a clinical-stage pharmaceutical company focused on developing the next generation of multi-mechanism oncology and anti-inflammatory drugs that target disease cells directly and the blood vessels that nourish them. EntreMed is focused on developing drugs that are safe and convenient, and provide the potential for improved patient outcomes. Panzem(R) (2-methoxyestradiol or 2ME2), the Company's lead drug candidate, is currently in clinical trials for cancer, as well as in preclinical development for non-oncology indications, including rheumatoid arthritis. The Company's goal is to develop and commercialize new compounds based on the Company's expertise in the science of angiogenesis angiogenesis /an·gio·gen·e·sis/ (-jen´e-sis) vasculogenesis; development of blood vessels either in the embryo or in the form of neovascularization or revascularization. an·gi·o·gen·e·sis n. , cell cycle regulation and inflammation -- processes vital to the treatment of cancer and other diseases. Company: Evotec AG Ticker Symbol & Exchange: EVT Investor Relations Contact: Anne Hennecke Investor Relations Contact Phone: +49-40-56081-286 Web: www.evotec.com Date of Presentation: 9 November 2005 Evotec is a leader in the discovery and development of novel small molecule drugs. Both through its own discovery programmes and through contract research partnerships, the Company is providing high quality research results to its partners in the pharmaceutical and biotechnology industry. In proprietary projects, Evotec specialises in finding new treatments for CNS diseases. Its lead compound, EVT EVT Eventueel (Danish: Maybe) EVT Extreme Value Theory (prediction tool for extrapolation of trend graphs) EVT Embedded Visual Tools EVT Emergency Vehicle Technician EVT Erstverkaufstag 201, is in clinical phase I for the treatment of insomnia. In addition, the Company has a number of products in late stage pre-clinical development, the most advanced of which, EVT 101 for the treatment of Alzheimer's disease, is expected to enter clinical trials later this year. In contract research, Evotec provides innovative solutions from target to clinic through an unmatched range of capabilities, incl. early stage assay development/screening through to medicinal chemistry/manufacturing. Company: GTC Biotherapeutics Ticker Symbol & Exchange: GTCB NASDAQ Investor Relations Contact: Thomas Newberry Investor Relations Contact Phone: 508-370-5374 Web: www.gtc-bio.com Date of Presentation: November 7, 2005 at 12:20 pm GTC GTC See: Good 'til cancelled order GTC See good-till-canceled order (GTC). Biotherapeutics is a leader in the development, production, and commercialization of therapeutic proteins through transgenic animal technology. GTC currently has five products in its internal pipeline and a portfolio of external program production opportunities. GTC's lead program is ATryn(R), its recombinant form of human antithrombin. A Market Authorization Application is under review by the European Medicines Agency The European Medicines Agency (EMEA) is a European agency for the evaluation of medicinal products. Until 2004, the European Medicines Agency was known as The European Agency for the Evaluation of Medicinal Products. Roughly parallel to the U.S. for the use of ATryn(R) in patients with a hereditary antithrombin deficiency. In its external programs, GTC's technology is used to develop transgenic production of its partners' proprietary products, including both large-volume protein therapeutics as well as products that are difficult to produce in significant quantities from conventional recombinant production systems. Company: Halozyme Therapeutics Ticker Symbol & Exchange: AMEX:HTI Investor Relations Contact: Don Markley, Vice President Investor Relations Contact Phone: (310) 691-7100 Web: www.halozyme.com Date of Presentation: Tuesday, November 8, 2005; 9:25 AM Halozyme is a biopharmaceutical company dedicated to developing and commercializing recombinant human enzymes for the infertility, ophthalmology, and oncology communities. The company's portfolio of products under development is based on intellectual property covering the family of human enzymes known as hyaluronidases. Halozyme's recombinant human enzymes may replace current animal slaughterhouse-derived enzymes that carry potential risks of animal pathogen transmission and immunogenicity immunogenicity /im·mu·no·ge·nic·i·ty/ (-je-nis´it-e) the property enabling a substance to provoke an immune response, or the degree to which a substance possesses this property. . The versatility of the first enzyme, rHuPH20, enables Halozyme to develop the product as a medical device, drug enhancement agent, and therapeutic biologic. Company: Hana Biosciences, Inc. Ticker Symbol & Exchange: AMEX: HBX Investor Relations Contact: Russell Skibsted Investor Relations Contact Phone: 650-588-6464 Web: www.hanabiosciences.com Date of Presentation: November 8, 2005, 9:45AM, Holmes II Hana Biosciences (AMEX AMEX See: American Stock Exchange : HBX HBX High-Explosive ) acquires, develops, and commercializes innovative products to advance cancer care. Product pipeline includes: (1) Talotrexin (PT-523), a novel nonpolyglutamatable antifolate drug which has demonstrated enhanced antitumor an·ti·tu·mor also an·ti·tu·mor·al adj. Counteracting or preventing the formation of malignant tumors; anticancer. Adj. 1. activity in a broad spectrum of cancers by targeting DHFR DHFR Dihydrofolate reductase, see there to prevent DNA synthesis and inhibit tumor growth in Ph I/II clinical trials in NSCLC NSCLC non (or cancer). NSCLC Non-small cell lung cancer, see there , ALL, and solid tumors;(2) Zensana(TM) (ondansetron oral spray), a novel, proprietary oral spray formulation of ondansetron that uses the highly-absorptive surfaces of the oral mucosa to deliver drug directly into the blood stream to prevent chemotherapy-induced nausea and vomiting Nausea and Vomiting Definition Nausea is the sensation of being about to vomit. Vomiting, or emesis, is the expelling of undigested food through the mouth. being developed under 505(b)(2) registration for 2007 launch; and(3) IPdR, a novel, orally available, thymidine thymidine /thy·mi·dine/ (thi´mi-den) thymine linked to ribose, a rarely occurring base in rRNA and tRNA; frequently used incorrectly to denote deoxythymidine. Symbol T. thy·mi·dine n. analogue and prodrug for IUdR, in Ph I clinical trials in colorectal, liver, gastric, and pancreatic cancers Company: Insmed Incorporated Ticker Symbol & Exchange: INSM Investor Relations Contact: Baxter Phillips, III Investor Relations Contact Phone: 804.565.3041 Web: www.insmed.com Date of Presentation: November 7, 2005 Insmed is a biopharmaceutical company focused on the discovery and development of drug candidates for the treatment of metabolic diseases and endocrine disorders with unmet medical needs. Company: INYX, INC. Ticker Symbol & Exchange: IYXI: OTCBB Investor Relations Contact: Jay M. Green, Executive VP Investor Relations Contact Phone: 212-838-1111 Web: www.inyxinc.com Date of Presentation: November 7, 2005 Inyx, Inc. is a specialty pharmaceutical company with niche drug delivery technologies and products for the treatment of respiratory, allergy, dermatological, topical and cardiovascular conditions. Inyx focuses its expertise on both prescription and over-the-counter pharmaceutical products, and provides specialty pharmaceutical development and production consulting services. In addition, Inyx is developing its own proprietary products to be marketed by selected clients and strategic partners. The company's operations are conducted through several wholly owned subsidiaries: Inyx USA, Ltd., based in Manati, Puerto Rico; Inyx Pharma Limited, near Manchester, England; Inyx Europe Limited, also near Manchester; Inyx Canada, Inc. in Toronto; and Exaeris, Inc., through which Inyx's strategic marketing collaborations are conducted. Inyx, Inc.'s corporate offices are in New York City. Company: Isotechnika Inc. Ticker Symbol & Exchange: ISA:TSX Investor Relations Contact: Stephanie Gillis-Paulgaard Investor Relations Contact Phone: 780-487-1600 extension 243 Web: www.isotechnika.com Date of Presentation: November 7th Isotechnika Inc. is an international biopharmaceutical company headquartered in Edmonton, Alberta, Canada. Drawing upon its expertise in medicinal chemistry and immunology, the Company is focused on the discovery and development of novel immunosuppressive Immunosuppressive Any agent that suppresses the immune response of an individual. Mentioned in: Antirheumatic Drugs, Graft-vs.-Host Disease, Immunosuppressant Drugs immunosuppressive 1. pertaining to or inducing immunosuppression. 2. therapeutics that are safer than currently available treatments. Isotechnika's lead compound, ISA (1) (Instruction Set Architecture) See instruction set. (2) (Interactive Services Association) See Internet Alliance. (3) (Internet Security and Acceleration) See .NET. 247 is an immunosuppressant immunosuppressant /im·mu·no·sup·pres·sant/ (-sah-pres´ant) an agent capable of suppressing immune responses. im·mu·no·sup·pres·sant n. An agent that suppresses the body's immune response. currently in a Canadian Phase III human clinical trial for the treatment of moderate to severe psoriasis. In addition, a Phase IIb kidney transplant trial with ISA247 will commence by the end of 2005. The Company also has two additional immunosuppressive compounds in its drug pipeline, TAFA TAFA Tonga Australian Football Association TAFA Thai Airfreight Forwarders Association TAFA The Arcade Flyer Archive (archive of advertising flyers for coin-op video, pinball and arcade games) TAFA Thermal Acoustic Fatigue Apparatus 93 and TKB TKB Terrorism Knowledge Base (National Memorial Institute for the Prevention of Terrorism) TKB Tappa Kegga Brew TKB The-Killer-Brothers (gaming clan) TKB Troubleshooting Knowledge Base TKB Task Builder 662 which are in Phase I and pre-clinical respectively. Company: Lipid Sciences, Inc. Ticker Symbol & Exchange: LIPD, Nasdaq Investor Relations Contact: Deborah S. Lorenz Investor Relations Contact Phone: 925-249-4031 Web: www.lipidsciences.com Date of Presentation: November 8, 2005 Lipid Sciences is a development-stage biotechnology company engaged in researching and developing products and processes to treat major medical indications, in which lipids (fat components) play a key role. The HDL (Hardware Description Language) A language used to describe the functions of an electronic circuit for documentation, simulation or logic synthesis (or all three). Although many proprietary HDLs have been developed, Verilog and VHDL are the major standards. Therapy platform (selective HDL delipidation and HDL mimetic mimetic /mi·met·ic/ (mi-met´ik) pertaining to or exhibiting imitation or simulation, as of one disease for another. mi·met·ic adj. 1. Of or exhibiting mimicry. 2. peptides) focuses on reversing plaque build-up in the vascular system and coronary arteries thereby reducing acute coronary events. The Viral Immunotherapy platform focuses on removing lipid coatings from lipid-enveloped viruses, through delipidation technology, to stimulate the body's immune system to fight disease. Conditions that could be impacted by this technology include HIV HIV (Human Immunodeficiency Virus), either of two closely related retroviruses that invade T-helper lymphocytes and are responsible for AIDS. There are two types of HIV: HIV-1 and HIV-2. HIV-1 is responsible for the vast majority of AIDS in the United States. , Hepatitis B and C, West Nile, SARS and influenza. Company: MaxCyte, Inc. Investor Relations Contact: Ronald Holtz, CFO Investor Relations Contact Phone: 301-944-1624 Web: www.maxcyte.com Date of Presentation: November 8, 2005 at 12:40 PM EST MaxCyte Inc. is a clinical stage company developing cell-based therapeutics primarily in the areas of oncology and regenerative medicine. MaxCyte's pipeline includes one product in Phase I/II clinical trials for the treatment of Chronic Lymphocytic Leukemia chronic lymphocytic leukemia n. Abbr. CLL Lymphocytic leukemia occurring mainly in older adults, characterized by slow onset and gradual progression of symptoms. (CLL CLL abbr. chronic lymphocytic leukemia CLL, n.pr See leukemia, chronic lymphocytic. CLL 1. Chronic lymphocytic leukemia 2. Cholesterol-lowering lipid ) and several preclinical candidates to treat a variety of diseases with unmet needs. The company also offers its unparalleled, customizable flow based cell loading technology to partners who take advantage of its advanced capabilities for cell-based therapeutic development and biotherapeutic (viral vector) manufacturing through licensing relationships. Partners are currently working to develop therapeutics for pulmonary, cardiovascular and infectious disease, cancer and regenerative medicine. Company: MEDICURE INC Ticker Symbol & Exchange: Amex: MCU & TSX: MPH Investor Relations Contact: HOGAN MULLALLY Investor Relations Contact Phone: 204-487-7412 Web: www.medicure.com Date of Presentation: Nov. 8, 2005 Medicure Inc. is a cardiovascular drug discovery and development Company focused on developing effective therapeutics for unmet needs in the field of cardiovascular medicine, the largest pharmaceutical market sector. The Company's solid position in this field is supported by the following attributes -- Cardiovascular focused pipeline: a global market of over US $70 billion -- Two drugs - MC-1 & MC-4232 - in advanced clinical development -- Three positive Phase II trials completed -- Unique products addressing major markets not adequately served by existing drugs -- Dual action antithrombotic, MC-45308, in preclinical testing Medicure also has a medicinal chemistry based Drug Discovery program focused on discovery and advancement of novel small molecule, anti-ischemics and anti-thrombotics towards human clinical studies. Company: MethylGene Inc. Ticker Symbol & Exchange: TSX : MYG Investor Relations Contact: Andrea Gilpin, Ph.D. Investor Relations Contact Phone: 514-337-3333 ext 416 Web: www.methylgene.com Date of Presentation: November 8, 2005 MethylGene is a biopharmaceutical specializing in cancer, antibiotic resistance, and other diseases such as diabetes, Huntington's, antifungals and inflammation. We currently have two compounds in human clinical trials: MGCD MGCD Maximum Gapless Coverage Distance 0103 and MG98. We have successfully partnered with Taiho Pharmaceutical, MGI MGI Mouse Genome Informatics MGI Modular Gateway Interface MGI McKinsey Global Institute MGI Military Geographic Information MGI Marine Geological Institute MGI Policy on the Management of Government Information (Canada) Pharma, Merck and EnVivo Pharmaceuticals. MethylGene's in-house medicinal chemistry group synthesizes compounds that specifically target enzymes involved in certain diseases such as cancer. The ability to synthesize specific compounds allows MethylGene to target diseased cells leaving healthy cells untouched. This is in contrast to other approaches such as chemotherapy or radiation therapy in which both healthy and diseased cells are affected causing unnecessary side effects. Our strength is in our ability to discover, to develop, and deliver target-specific drugs. Company: MicroIslet Inc. Ticker Symbol & Exchange: Amex: MII Investor Relations Contact: Bill Kachioff Investor Relations Contact Phone: 858-657-0287 Web: www.microislet.com Date of Presentation: 11/8/05 MicroIslet is a biotechnology company engaged in the research, development, and commercialization of patented technologies in the field of transplantation therapy for people with insulin-dependent diabetes. MicroIslet's patented islet islet /is·let/ (-lit) an island. islets of Langerhans irregular microscopic structures scattered throughout the pancreas and comprising its endocrine portion. transplantation technology includes methods for isolating, culturing, cryopreservation cryopreservation /cryo·pres·er·va·tion/ (-prez?er-va´shun) maintenance of the viability of excised tissue or organs by storing at very low temperatures. cry·o·pres·er·va·tion n. , and immuno-protection (microencapsulation microencapsulation a manufacturing process in which an active agent is contained in microcapsules, suspended in a liquid. As the vehicle dries, the capsules dry out and the contents become active. ) of islet cells. MicroIslet is working to develop and commercialize a first product, called MicroIslet-Px(TM), a microencapsulated microencapsulated Therapeutics adjective Surrounded by a thin layer of biodegradable substance–eg, a microsphere, as a means of protecting a drug or vaccine antigen from rapid breakdown, or of enhancing antigenic absorption and immune response thereto porcine porcine /por·cine/ (por´sin) pertaining to swine. porcine pertaining to pig. See also hog (1), swine. porcine circovirus 1 a nonpathogenic virus. islet cell suspension that will be used for transplantation in patients with insulin-dependent diabetes. Additional information about MicroIslet can be found at www.microislet.com. Company: Neoprobe Corporation Ticker Symbol & Exchange: NEOP (OTCBB) Investor Relations Contact: Brent Larson Investor Relations Contact Phone: 614.793.7500 x133 Web: www.neoprobe.com Date of Presentation: November 8, 2005 (1:00p.m.) Neoprobe is a biomedical bi·o·med·i·cal adj. 1. Of or relating to biomedicine. 2. Of, relating to, or involving biological, medical, and physical sciences. company focused on developing and commercializing innovative products that enhance patient care and improve patient outcome. Neoprobe currently markets the neo2000(R) line of gamma detection systems that are widely used by cancer surgeons and is commercializing the Quantix(R) line of blood flow measurement products. Neoprobe holds significant interests in the development of related biomedical systems and radiopharmaceutical radiopharmaceutical /ra·dio·phar·ma·ceu·ti·cal/ (-fahr?mah-soo´ti-k'l) a radioactive pharmaceutical, nuclide, or other chemical used for diagnostic or therapeutic purposes. agents including Lymphoseek(TM) and RIGScan(R) CR. Neoprobe's subsidiary, CIRA Biosciences, Inc., is also advancing a patient-specific cellular therapy technology platform called ACT. Neoprobe's strategy is to deliver superior growth and shareholder return by maximizing its strong position in gamma detection technologies and diversifying into new, synergistic biomedical markets through continued investment and selective acquisitions. Company: NeuroHealing Pharmaceuticals, Inc. Investor Relations Contact: Daniel Katzman Investor Relations Contact Phone: 617 331-4111 Web: www.neurohealing.com Date of Presentation: November 8, 2005 NeuroHealing is a private, clinical stage company developing therapeutics to improve the functional outcome of post-acute neurorehabilitation patients, including disorders such as traumatic brain injury Traumatic brain injury (TBI), traumatic injuries to the brain, also called intracranial injury, or simply head injury, occurs when a sudden trauma causes brain damage. TBI can result from a closed head injury or a penetrating head injury and is one of two subsets of acquired brain , stroke, Parkinson's disease and other motor neuron diseases. NeuroHealing is developing three reprofiled drug candidates, each with early evidence of clinical efficacy, extensive human safety data and featuring formulation and drug delivery strategies:NH001 is designed to accelerate the recovery and improve the functional outcome of patients from a coma, vegetative vegetative /veg·e·ta·tive/ (vej?e-ta?tiv) 1. of, pertaining to, or characteristic of plants. 2. concerned with growth and nutrition, as opposed to reproduction. 3. or minimally conscious state A minimally conscious state (MCS) is a condition distinct from coma or the vegetative state, in which a patient exhibits deliberate, or cognitively mediated, behavior often enough, or consistently enough, for clinicians to be able to distinguish it from entirely unconscious, following a traumatic brain injury. NH004 is a novel treatment for sialorrhea sialorrhea /si·a·lor·rhea/ (-re´ah) ptyalism. si·a·lor·rhe·a or si·a·lor·rhoe·a n. See ptyalism. (drooling drooling the discharge of saliva from the mouth. A normal feature in some breeds of dogs such as St. Bernard, Newfoundland and English bulldog, presumably because of their loose, pendulous lips. ), an embarrassing complication in Parkinson's, Cerebral Palsy and other neurological conditions. NH02D is designed to improve the rehabilitation outcomes of stroke patients. Company: NovaDel Pharma Ticker Symbol & Exchange: AMEX NVD Investor Relations Contact: Michael Spicer Investor Relations Contact Phone: Michael Spicer, 908.782.3431 X2550 Web: www.novadel.com Date of Presentation: November 7, 2005 NovaDel Pharma Inc. is a specialty pharmaceutical company that is developing a novel drug-delivery system for both prescription and over-the-counter therapeutics. The Company's proprietary technology uses an oral spray to rapidly deliver drugs into the systemic circulation. The technology can be applied to a variety of drugs in the Rx, OTC OTC See: Over-the-counter. OTC See over-the-counter market (OTC). and veterinary therapeutic areas. Drugs administered in a spray form to the oral mucosa have the potential for a) faster onset of action onset of action Pharmacology The length of time needed for a medicine to become effective. See Therapeutic drug monitoring. , b) improved safety profile and c) enhanced patient compliance. Company: OrthoLogic Corp. Ticker Symbol & Exchange: OLGC Investor Relations Contact: Sherry Sturman Investor Relations Contact Phone: 602-286-5436 Web: www.orthologic.com Date of Presentation: Monday, November 7, 2005 8:00 a.m. OrthoLogic is a biotechnology company focused on the development and commercialization of the novel synthetic peptide Chrysalin(R) (TP508) in three lead indications, all of which represent areas of significant unmet medical need - fracture repair, diabetic foot ulcer healing and cartilage defect repair. Based on the Company's pioneering scientific research of the natural healing cascade, OrthoLogic has become the leading company focused on tissue and bone repair. OrthoLogic is committed to developing a pipeline of novel peptides and other molecules aimed at helping patients with unmet medical needs and under-served conditions. The Company maintains exclusive worldwide rights for Chrysalin. Company: OXiGENE, Inc. Ticker Symbol & Exchange: Nasdaq/XSSE: OXGN Investor Relations Contact: Susan Hager Investor Relations Contact Phone: 781-547-5900 Web: www.oxigene.com Date of Presentation: Nov. 8, 2005 OXiGENE is an emerging pharmaceutical company developing novel small-molecule therapeutics to treat cancer and eye diseases. The Company's major focus is the clinical advancement of drug candidates that selectively disrupt abnormal blood vessels associated with solid tumor progression and visual impairment. OXiGENE is dedicated to leveraging its intellectual property position and therapeutic development expertise to bring life saving and enhancing medicines to patients. Company: PAION Ticker Symbol & Exchange: PA8 Investor Relations Contact: Dr. Peer Nils Schroder Investor Relations Contact Phone: +49-241-4453-152 Web: www.paion.de Date of Presentation: 7.11.2005, 10.10 a.m. PAION, a biopharmaceutical company based in Aachen, Germany, aims to become a leader in developing and commercialising innovative drugs for the treatment of stroke and other thrombotic diseases for which there is a substantial unmet medical need. PAION intends to build an integrated drug portfolio by exploiting its expertise in identifying compounds, licensing or otherwise acquiring them and advancing them through the clinical development and regulatory approval process. PAION's lead product Desmoteplase for the treatment of acute ischaemic stroke is currently in Phase III. During the first half-year 2005, PAION employed on average 59 people. Company: Panacos Pharmaceuticals, Inc. Ticker Symbol & Exchange: PANC (Nasdaq) Investor Relations Contact: Jill Smith Investor Relations Contact Phone: 240.631.1395 x-1250 Web: http://www.panacos.com Date of Presentation: November 7, 2005 Panacos is developing the next generation of anti-infective products through discovery and development of small molecule oral drugs for the treatment of HIV and other major human viral diseases. Panacos' proprietary discovery technologies and lead therapeutic candidate, PA-457, focus on novel targets in the virus life cycle, including virus maturation and virus fusion. Company: PharmaFrontiers Corp. Ticker Symbol & Exchange: PFTR.OB Investor Relations Contact: C. W. "Bill" Rouse, CFO Investor Relations Contact Phone: 281-775-0608 Web: www.pharmafrontierscorp.com Date of Presentation: November 9, 2005 (9:45 AM) Kennedy II PharmaFrontiers' strategy is to develop and commercialize cell therapies to treat several major disease areas such as cardiac and pancreatic conditions and Multiple Sclerosis. PharmaFrontiers owns patented and proprietary individualized cell therapies that are in FDA Phase I/II human dose ranging clinical trials to evaluate their safety and effectiveness in treating MS. The company also holds the exclusive worldwide license from the University of Chicago, through its prime contractor relationship with Argonne National Laboratory Argonne National Laboratory, research center, based in Argonne, Ill., 27 mi (43 km) SW of downtown Chicago, with other facilities at the Idaho National Engineering Laboratory, 50 mi (80 km) W of Idaho Falls, Idaho. Founded in 1946 by the U.S. , for patents relating to the use of adult pluripotent stem cells derived from patients' own circulating blood. Company: Protein Polymer Technologies, Inc. Ticker Symbol & Exchange: OTC BB: PPTI Investor Relations Contact: Erin Davis Investor Relations Contact Phone: (858) 558-6064 x 120 Web: www.ppti.com Date of Presentation: Wednesday, November 9, 2005 Protein Polymer Technologies, Inc. is a biotechnology company that discovers and develops innovative therapeutic devices to improve medical and surgical outcomes. The Company focuses on developing technology and products to be used for soft tissue augmentation, tissue adhesives and sealants, wound healing support and drug delivery devices. Protein Polymer Technologies' proprietary protein-based biomaterials are uniquely tailored to optimize clinical performance and contain no human or animal components that could potentially transmit or cause disease. The company is headquartered in San Diego, California “San Diego” redirects here. For other uses, see San Diego (disambiguation). San Diego is a coastal Southern California city located in the southwestern corner of the continental United States. As of 2006, the city has a population of 1,256,951. . For additional information about the company, please visit www.ppti.com. Company: Regeneration Technologies, Inc. Ticker Symbol & Exchange: RTIX, NASDAQ Investor Relations Contact: Wendy Crites Wacker Investor Relations Contact Phone: (386) 418-8888 Web: www.rtix.com Date of Presentation: November 8, 2005 RTI RTI - Return from interrupt processes allograft allograft: see transplantation, medical. and xenograft xenograft /xeno·graft/ (zen´o-graft) a graft of tissue transplanted between animals of different species; it may be concordant, tissue into shaped implants for use in orthopedic, cardiovascular and other surgeries with a commitment to science, safety and innovation. RTI also holds the patents on BioCleanse(R), the only proven tissue sterilization process validated to eliminate viruses, bacteria, fungi and spores from tissue without impacting the structural or biomechanical integrity of the tissue. The company has distributed more than 600,000 allograft implants sterilized ster·il·ize tr.v. ster·il·ized, ster·il·iz·ing, ster·il·iz·es 1. To make free from live bacteria or other microorganisms. 2. with the BioCleanse process with zero incidence of infection. RTI is accredited accredited recognition by an appropriate authority that the performance of a particular institution has satisfied a prestated set of criteria. accredited herds cattle herds which have achieved a low level of reactors to, e.g. by the American Association of Tissue Banks and was named a 2004 Technology Pioneer by the World Economic Forum. Company: Santarus Inc. Ticker Symbol & Exchange: Nasdaq: SNTS Investor Relations Contact: Jody Cain, Senior VP Investor Relations Contact Phone: (310) 691-7100 Web: www.santarus.com Date of Presentation: Wed., November 9, 2005, 9:25 AM Santarus, Inc. is a specialty pharmaceutical company focused on acquiring, developing and commercializing proprietary products to enhance the quality of life for patients with gastrointestinal diseases and disorders. The company's current products are immediate-release formulations of omeprazole, a widely prescribed proton pump inhibitor proton pump inhibitor n. A class of drugs that inhibit gastric acid secretion by interfering with the movement of hydrogen ions across cell membranes and are used mainly to treat peptic ulcers, gastroesophageal reflux disease, and esophagitis. (PPI (1) (Pixels Per Inch) The measurement of the resolution of a monitor or scanner. For example, a monitor that is 16 inches wide and displays 1600 pixels across its width would have a resolution of 100 ppi (1600 divided by 16). ). The company launched its first product, ZEGERID(R) Powder for Oral Suspension 20 mg, in October 2004 and launched ZEGERID Powder for Oral Suspension 40 mg in February 2005. The company submitted a New Drug Application (NDA (Non Disclosure Agreement) An agreement signed between two parties that have to disclose confidential information to each other in order to do business. In general, the NDA states why the information is being divulged and stipulates that it cannot be used for any ) for ZEGERID Capsules to the U.S. Food and Drug Administration (FDA) in April 2005 and submitted an NDA for ZEGERID Chewable Tablets to the FDA in May 2005. More information about Santarus is available on the company's Web site at www.santarus.com. Company: Solexa Inc. Ticker Symbol & Exchange: Nasdaq: SLXA Investor Relations Contact: Jody Cain, Senior VP Investor Relations Contact Phone: (310) 691-7100 Web: www.solexa.com Date of Presentation: Tuesday, November 8, 2005; 4:35 PM Solexa is developing and preparing to commercialize a new genetic analysis instrument system which will be used to perform a range of analyses including whole genome resequencing, gene expression analysis and micro-RNA analysis. Solexa scientists have sequenced a human bacterial artificial chromosome A bacterial artificial chromosome (BAC) is a DNA construct, based on a fertility plasmid (or F-plasmid), used for transforming and cloning in bacteria, usually E. coli. , an important milestone demonstrating that its technology can be applied to resequence human DNA DNA: see nucleic acid. DNA or deoxyribonucleic acid One of two types of nucleic acid (the other is RNA); a complex organic compound found in all living cells and many viruses. It is the chemical substance of genes. . Solexa expects its first-generation technology to generate over a billion bases of DNA sequence per run and to enable whole genome resequencing below $100,000 per sample, making it the first platform to reach this important milestone. Solexa's longer-term goal is to reduce the cost of human resequencing to a few thousand dollars for use in a wide range of applications from basic research through clinical diagnostics. Solexa expects to introduce its first instrument system by the end of 2005. Company: Spectranetics Corporation Ticker Symbol & Exchange: Nasdaq: SPNC Investor Relations Contact: Don Markley, Vice President Investor Relations Contact Phone: (310) 691-7100 Web: www.cytrx.com Date of Presentation: Wed., November 9, 2005; 11:55 AM Spectranetics is a medical device company that develops, manufactures and markets single-use medical devices used in minimally invasive surgical procedures within the cardiovascular system in conjunction with its proprietary excimer laser system. Its CVX-300(R) excimer laser is the only system approved by the FDA for multiple cardiovascular procedures, including coronary atherectomy, and the removal of problematic pacemaker and defibrillator defibrillator, device that delivers an electrical shock to the heart in order to stop certain forms of rapid heart rhythm disturbances (arrhythmias). The shock changes a fibrillation to an organized rhythm or changes a very rapid and ineffective cardiac rhythm to a leads. Nearly all of the company's FDA-approved and investigational applications have received Communautes Europeennes (CE) mark registration for marketing within Europe. In April 2004 Spectranetics obtained 510(k) clearance from the FDA for the laser-based treatment of patients suffering from total occlusions (blockages) in their leg arteries that are not crossable with a guide wire. Company: StemCells, Inc. Ticker Symbol & Exchange: Nasdaq: STEM Investor Relations Contact: Rodney Young, CFO Investor Relations Contact Phone: 650 475 3100 ext 105 Web: www.stemcellsinc.com Date of Presentation: November 7, 2005 StemCells, Inc. is developing stem cell therapeutics using adult stem cell Adult stem cells are undifferentiated cells found throughout the body that divide to replenish dying cells and regenerate damaged tissues. Also known as somatic (from Greek Σωματικóς, of the body technology. The Company to date has discovered the human neural stem cell (HuCNS-SC(TM)) and candidate liver and pancreatic stem cells. StemCells has over 40 issued US patents in the neural stem cell field. StemCells' initial target indications are lysosomal storage diseases lysosomal storage diseases A heterogeneous group of diseases with specific lysosomal enzyme defects. Cf Inborn errors of metabolism. that affect the CNS, and in October 2005, the FDA cleared the Company to begin a Phase I clinical trial in Batten disease. This will be the first FDA-approved trial to transplant human neural stem cells. StemCells is continuing preclinical evaluation of HuCNS-SC as a treatment for spinal cord injury Spinal Cord Injury Definition Spinal cord injury is damage to the spinal cord that causes loss of sensation and motor control. Description Approximately 10,000 new spinal cord injuries (SCIs) occur each year in the United States. , stroke and other CNS indications. Company: TRANSGENE Ticker Symbol & Exchange: TRGNY (Pink Sheets) Investor Relations Contact: Philippe Poncet Investor Relations Contact Phone: + 33 3 88 27 91 21 Web: www.transgene.fr Date of Presentation: November 8, 2005 Transgene transgene a gene that has been incorporated into the genome of another organism. is a France-based biopharmaceutical company dedicated to the development of therapeutic vaccines and immunotherapeutic products in oncology and infectious diseases. The company has three compounds in Phase II trials and one compound in Phase I study. Transgene has bio-manufacturing capacities for the production of viral-based vectors (adenovirus adenovirus Any of a group of spheroidal viruses, made up of DNA wrapped in a protein coat, that cause sore throat and fever in humans, hepatitis in dogs, and several diseases in fowl, mice, cattle, pigs, and monkeys. and vaccinia virus) and technologies available for out-licensing. By developing expertise in applied research, clinical and production capabilities (2800 sq. meter GMP GMP (guanosine monophosphate): see guanine. production facility) while maintaining broad intellectual property of over 200 patent families, Transgene is uniquely poised to advance cancer and infectious diseases therapies through both in-house and partnered development. Company: Transition Therapeutics Ticker Symbol & Exchange: TTH Investor Relations Contact: Soraya Centeno Investor Relations Contact Phone: 416 260 7770 ext. 243 Web: www.transitiontherapeutics.com Date of Presentation: November 8th at 11:55am Transition Therapeutics is a product-focused biopharmaceutical company, developing novel therapeutics for disease indications with large markets. The company's strategy is to develop multiple products in parallel, thereby leveraging its internal resources and expertise across many opportunities. Transition's development focus is to concentrate on preclinical products that can be quickly advanced to Phase II trials for large disease indications. Transition is currently developing five products that target diabetes (Type I and II), multiple sclerosis, hepatitis C and Alzheimer's disease (Alzheimer's disease-modifying therapy). Transition's robust product pipeline and recent licensing agreement with leading diabetes company Novo Nordisk demonstrate the Company's ability to develop multiple clinical programs in parallel and attract large pharma partnerships. Company: VioQuest Pharmaceuticals Ticker Symbol & Exchange: OTCBB: VQPH Investor Relations Contact: Amanda Watkins Investor Relations Contact Phone: 212-825-3210 Web: www.vioquestpharm.com Date of Presentation: November 9, @ 10:10 AM VioQuest Pharmaceuticals, Inc. acquires and develops targeted late preclinical and early clinical stage therapies with unique mechanisms of action for oncology, viral and autoimmune disorders. The Company is developing two novel anti-cancer agents VQD-001 and VQD-002 for the treatment of melanoma, myeloma myeloma /my·elo·ma/ (mi?e-lo´mah) a tumor composed of cells of the type normally found in the bone marrow. giant cell myeloma see under tumor (1). , lymphoma; and breast, ovarian, pancreatic, colorectal cancers, respectively. VioQuest's subsidiary, Chiral chi·ral adj. Of or relating to the structural characteristic of a molecule that makes it impossible to superimpose it on its mirror image. chi·ral Quest, Inc., a pioneer in asymmetric synthesis, offers proprietary chiral catalysts and synthesis expertise for creating important chiral intermediates and products, which improves the safety, efficacy and manufacturing efficiency of pharmaceutical products. Chiral Quest provides products and services to twelve of the top eighteen pharmaceutical companies worldwide. Company: ZIOPHARM Oncology Ticker Symbol & Exchange: ZIOP.OB Investor Relations Contact: Kelly Luethje & Suzanne McKenna Investor Relations Contact Phone: 617-259-1975/ 646-214-0703 Web: www.ziopharm.com Date of Presentation: 8:40-9:00 am ZIOPHARM Oncology, Inc. is a biopharmaceutical company seeking to acquire, develop and commercialize a diverse, risk-sensitive portfolio of in-licensed cancer drugs that address unmet medical needs. Currently, the Company is in U.S. phase I studies for its two product candidates, ZIO-101 and ZIO-201. Company: ZymoGenetics Ticker Symbol & Exchange: NASDAQ: ZGEN Investor Relations Contact: John Calhoun Investor Relations Contact Phone: 206-442-6744 Web: www.zymogenetics.com Date of Presentation: November 7, 2005 ZymoGenetics is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutic proteins for the prevention or treatment of human diseases. The Company is developing a diverse pipeline of potential proprietary product candidates that are moving into and through clinical development. These span a wide array of clinical opportunities that include bleeding, autoimmune diseases and cancer. ZymoGenetics intends to commercialize these product candidates through internal development, collaborations with partners, and out-licensing of patents from its extensive patent portfolio. For further information, visit www.zymogenetics.com. Note to Editors: Business Wire's PressPass allows you to create free, custom Web, RSS (Really Simple Syndication) A syndication format that was developed by Netscape in 1999 and became very popular for aggregating updates to blogs and the news sites. RSS has also stood for "Rich Site Summary" and "RDF Site Summary. , and email-based news feeds from more than 160 industry options, dozens of subject categories and thousands of geographic preferences as well as by specific company filters. In addition, PressPass subscribers have access to exclusive content to experts, company profiles, email alerts, survey services and other media services. Note to Event Organizers: Add your trade show, conference, or event to www.tradeshownews.com, Business Wire's online event calendar. For information, email tradeshow@businesswire.com. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion